ArticleBiomaterials2014
Multivesicular liposomal bupivacaine at the sciatic nerve.
Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Randomized, Double-Blinded, Allocation Concealed Study Comparing the Efficacy of Liposomal Bupivacaine Over Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Primary Total Knee Arthroplasty
Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia: A Randomized Clinical Trial
Who cites it
58 citing papers in PubMed, 134 citations in OpenAlex.
- Comparison of Liposomal Bupivacaine versus Bupivacaine in Superficial Parasternal Intercostal Plane Block for Cardiac Surgery with Median Sternotomy.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2025Trial
- Effects of Extended-Release Liposomal Bupivacaine on Postoperative Mechanical and Thermal Hypersensitivity in C57BL/6 Mice (Mus musculus).Journal of the American Association for Laboratory Animal Science : JAALAS · 2026Article
- Carboxylated prodrug of capsaicin with enhanced peripheral nerve permeation mediated by monocarboxylate transporters for long-lasting local anesthesia.Acta pharmaceutica Sinica. B · 2026Article
- Evolving Trends and Core Contributors: A Bibliometric Update on Liposomal Bupivacaine.Pain research & management · 2026Article
- Injectable Microparticle-Nanoliposome Hydrogel for Extended Release of Small Hydrophilic Molecules.ACS nano · 2025Article
- Enhanced Control of Liposomal Drug Release by Drug-Aptamer Complexes.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- The impact of product quality attributes on in vivo performance of bupivacaine multivesicular liposomes.Drug delivery and translational research · 2025Article
- Glucose-Facilitated Nanomicelles Cross Peripheral Nerve Barriers to Achieve Drug Delivery to Nerves.Advanced functional materials · 2025Article
- Electrodiagnostic Assessment of Peri-Procedural Iatrogenic Peripheral Nerve Injuries and Rehabilitation.Muscle & nerve · 2025Review
- Tetrodotoxin Delivery Pen Safely Uses Potent Natural Neurotoxin to Manage Severe Cutaneous Pain.Advanced healthcare materials · 2025Article
- Trends and Hotspots in Nanomedicine Applications for Pain: A Bibliometric Analysis from 1999 to 2024.ACS omega · 2025Article
- A carrier-free long-acting ropivacaine formulation using methylprednisolone sodium succinate as a dual-functional adjuvant.Theranostics · 2025Article
- Application of cell-derived vesicle-based biomimetic drug delivery system in tumor therapy.Frontiers in pharmacology · 2025Review
- Innovative Approaches to Enhancing the Biomedical Properties of Liposomes.Pharmaceutics · 2024Review
- Exosomal Bupivacaine: Integrating Nerve Barrier Penetration Capability and Sustained Drug Release for Enhanced Potency in Peripheral Nerve Block and Reduced Toxicity.Advanced functional materials · 2024Article
- Polymeric Prodrugs using Dynamic Covalent Chemistry for Prolonged Local Anesthesia.Angewandte Chemie (International ed. in English) · 2024Article
- Galacturonic acid-capsaicin prodrug for prolonged nociceptive-selective nerve blockade.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Article
- Long-term sensorimotor changes after a sciatic nerve block with bupivacaine and liposomal bupivacaine in a high-fat diet/low-dose streptozotocin rodent model of diabetes.Frontiers in anesthesiology · 2024Article
- Size control of ropivacaine nano/micro-particles by soft-coating with peptide nanosheets for long-acting analgesia.Theranostics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Clinical translation of sustained release formulations for local anesthetics has been limited by adverse tissue reaction. Exparel™ (DepoFoam bupivacaine) is a new liposomal local anesthetic formulation whose biocompatibility near nerve tissue is not well characterized. Exparel™ injection caused sciatic nerve blockade in rats lasting 240 min compared to 120 min for 0.5% (w/v) bupivacaine HCl and 210 min for 1.31% (w/v) bupivacaine HCl (same bupivacaine content as Exparel™). On histologic sections four days after injection, median inflammation scores in the Exparel™ group (2.5 of 4) were slightly higher than in groups treated with bupivacaine solutions (score 2). Myotoxicity scores in the Exparel™ group (2.5 of 6) were similar to in the 0.5% (w/v) bupivacaine HCl group (3), but significantly less than in the 1.31% (w/v) bupivacaine HCl group (5). After two weeks, inflammation from Exparel™ (score 2 of 6) was greater than from 0.5% (w/v) bupivacaine HCl (1) and similar to that from 1.31% (w/v) bupivacaine HCl (1). Myotoxicity in all three groups was not statistically significantly different. No neurotoxicity was detected in any group. Tissue reaction to Exparel™ was similar to that of 0.5% (w/v) bupivacaine HCl. Surveillance for local tissue injury will be important during future clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.